Through its ubiquitin-editing activity, TNFAIP3 modulates both NF-κB–driven inflammation and NRF2-mediated antioxidant responses, representing a potential therapeutic target for COPD–insomnia comorbidity [38]. This evidence concerns the gene TNFAIP3 and insomnia measurement.